AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Clinical trial NCT06767527 · RECRUITING

Trial details

NCT number: NCT06767527
Sponsor: Akeso
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Triple-Negative Breast Cancer (TNBC)

Start date: 2025-02-07
Primary completion: 2026-12-01
Enrollment: 416

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.